Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
roche
28
×
life sciences
national blog main
national top stories
biotech
boston blog main
boston top stories
san francisco blog main
san francisco top stories
cancer
national
clinical trials
deals
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
wisconsin blog main
wisconsin top stories
detroit blog main
detroit top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
fda
boulder/denver blog main
boulder/denver top stories
indiana blog main
indiana top stories
novartis
pfizer
investing
amgen
genentech
merck
startups
biogen
What
drug
cancer
roundup
bio
fda
medical
medicine
roche
gene
new
annual
crispr
data
latest
medicines
patients
society
therapy
approval
big
clinical
companies
conference
genetic
intended
life
oncology
research
therapeutics
today
advanced
ahead
american
approved
asco
ash
billion
blood
blueprint
ceo
Language
unset
unknown
Current search:
roche
×
@bgr.com
4 years ago
This groundbreaking new coronavirus cure is unlike any other drug we’ve seen so far
@xconomy.com
4 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
4 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
Venture Investors Bets on Healthcare, and Milwaukee, With $75M Fund
@xconomy.com
5 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
5 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
5 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@techcrunch.com
5 years ago
Only 2% of genomic material available for research comes from Africa, 54gene wants to change that
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Meet the Xconomy Awards San Diego Digital Trailblazer Finalists
@techcrunch.com
5 years ago
Healthcare by 2028 will be doctor-directed, patient-owned and powered by visual technologies
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
6 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
6 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More